KalVista Q2 2025 Earnings Report

Reported second quarter fiscal year results and provided operational update

Key Takeaways

KalVista Pharmaceuticals reported no revenue for the second fiscal quarter ended October 31, 2024. The company's research and development expenses were $16.6 million, while general and administrative expenses were $29.2 million. The company had cash, cash equivalents and marketable securities of $135.8 million, with a pro forma balance of $292.2 million.

FDA accepted the New Drug Application (NDA) for sebetralstat with a PDUFA goal date of June 17, 2025.

Filed Marketing Authorization Applications (MAA) to regulatory authorities in the United Kingdom, Switzerland, Australia and Singapore.

Presented new sebetralstat data at the 2024 American College of Allergy Asthma and Immunology and the 2024 HAEi Global Angioedema Forum.

Raised $160 million in aggregate gross proceeds through concurrent synthetic royalty financing and equity offerings.